HanBio Therapeutics Funding: $40M Raised, Series A (2022)
HanBio Therapeutics is based in Shanghai, China. It has raised $40M in total funding. Latest round: Series A.
HanBio Therapeutics funding overview
HanBio Therapeutics is based in Shanghai, China. HanBio Therapeutics has raised $40M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in January 2022. The round record for HanBio Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include OrbiMed, Hankang Capital, Yonghua Investment, Elikon Investment. 4 distinct backers are named across the disclosed rounds.
Frequently asked about HanBio Therapeutics funding
How much has HanBio Therapeutics raised?
HanBio Therapeutics has raised $40M in total disclosed funding across the rounds on record.
Who has invested in HanBio Therapeutics?
OrbiMed, Hankang Capital, Yonghua Investment, Elikon Investment are named among the investors backing HanBio Therapeutics.
What was the latest HanBio Therapeutics funding round?
The most recent disclosed round is a Series A, announced in January 2022.
Where is HanBio Therapeutics based?
HanBio Therapeutics is based in Shanghai, China.
When did HanBio Therapeutics last raise?
The last disclosed HanBio Therapeutics round closed in January 2022 at Series A.
HanBio Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shanghai below to benchmark round size and investor mix.
